Safety profile of rivaroxaban in first-time users treated for venous thromboembolism in four European countries.
<h4>Background</h4>The European rivaroxaban post-authorization safety study evaluated bleeding risk among patients initiated on rivaroxaban or vitamin K antagonists for the treatment and secondary prevention of venous thromboembolism in routine clinical practice.<h4>Methods</h4&...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2024-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0298596&type=printable |
| _version_ | 1797263515178762240 |
|---|---|
| author | Ana Ruigómez Tania Schink Annemarie Voss Ron M C Herings Elisabeth Smits Karin Swart-Polinder Yanina Balabanova Gunnar Brobert Kiliana Suzart-Woischnik Luis Alberto García Rodríguez |
| author_facet | Ana Ruigómez Tania Schink Annemarie Voss Ron M C Herings Elisabeth Smits Karin Swart-Polinder Yanina Balabanova Gunnar Brobert Kiliana Suzart-Woischnik Luis Alberto García Rodríguez |
| author_sort | Ana Ruigómez |
| collection | DOAJ |
| description | <h4>Background</h4>The European rivaroxaban post-authorization safety study evaluated bleeding risk among patients initiated on rivaroxaban or vitamin K antagonists for the treatment and secondary prevention of venous thromboembolism in routine clinical practice.<h4>Methods</h4>Cohorts were created using electronic healthcare databases from the UK, the Netherlands, Germany and Sweden. Patients with a first prescription of rivaroxaban or vitamin K antagonist during the period from December 2011 (in the UK, January 2012) to December 2017 (in Germany, December 2016) for venous thromboembolism indication, with no record of atrial fibrillation or recent cancer history, were observed until the occurrence of each safety outcome (hospitalization for intracranial, gastrointestinal, urogenital or other bleeding), death or study end (December 2018; in Germany, December 2017). Crude incidence rates of each outcome per 100 person-years were computed.<h4>Results</h4>Overall, 44 737 rivaroxaban and 45 842 vitamin K antagonist patients were enrolled, mean age, 59.9-63.8 years. Incidence rates were similar between rivaroxaban and vitamin K antagonist users with some exceptions, including higher incidence rates for gastrointestinal bleeding in rivaroxaban users than in vitamin K antagonist users. Among rivaroxaban users, mortality and bleeding risk generally increased with age, renal impairment and diabetes.<h4>Conclusions</h4>This study provides further data from routine clinical practice that broadly support safety profile of rivaroxaban for VTE indication and complement findings from previous randomized clinical trials. |
| first_indexed | 2024-04-25T00:14:14Z |
| format | Article |
| id | doaj.art-21563d3bc5d248d7917f16c59b0f6158 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-25T00:14:14Z |
| publishDate | 2024-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-21563d3bc5d248d7917f16c59b0f61582024-03-13T05:31:31ZengPublic Library of Science (PLoS)PLoS ONE1932-62032024-01-01193e029859610.1371/journal.pone.0298596Safety profile of rivaroxaban in first-time users treated for venous thromboembolism in four European countries.Ana RuigómezTania SchinkAnnemarie VossRon M C HeringsElisabeth SmitsKarin Swart-PolinderYanina BalabanovaGunnar BrobertKiliana Suzart-WoischnikLuis Alberto García Rodríguez<h4>Background</h4>The European rivaroxaban post-authorization safety study evaluated bleeding risk among patients initiated on rivaroxaban or vitamin K antagonists for the treatment and secondary prevention of venous thromboembolism in routine clinical practice.<h4>Methods</h4>Cohorts were created using electronic healthcare databases from the UK, the Netherlands, Germany and Sweden. Patients with a first prescription of rivaroxaban or vitamin K antagonist during the period from December 2011 (in the UK, January 2012) to December 2017 (in Germany, December 2016) for venous thromboembolism indication, with no record of atrial fibrillation or recent cancer history, were observed until the occurrence of each safety outcome (hospitalization for intracranial, gastrointestinal, urogenital or other bleeding), death or study end (December 2018; in Germany, December 2017). Crude incidence rates of each outcome per 100 person-years were computed.<h4>Results</h4>Overall, 44 737 rivaroxaban and 45 842 vitamin K antagonist patients were enrolled, mean age, 59.9-63.8 years. Incidence rates were similar between rivaroxaban and vitamin K antagonist users with some exceptions, including higher incidence rates for gastrointestinal bleeding in rivaroxaban users than in vitamin K antagonist users. Among rivaroxaban users, mortality and bleeding risk generally increased with age, renal impairment and diabetes.<h4>Conclusions</h4>This study provides further data from routine clinical practice that broadly support safety profile of rivaroxaban for VTE indication and complement findings from previous randomized clinical trials.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0298596&type=printable |
| spellingShingle | Ana Ruigómez Tania Schink Annemarie Voss Ron M C Herings Elisabeth Smits Karin Swart-Polinder Yanina Balabanova Gunnar Brobert Kiliana Suzart-Woischnik Luis Alberto García Rodríguez Safety profile of rivaroxaban in first-time users treated for venous thromboembolism in four European countries. PLoS ONE |
| title | Safety profile of rivaroxaban in first-time users treated for venous thromboembolism in four European countries. |
| title_full | Safety profile of rivaroxaban in first-time users treated for venous thromboembolism in four European countries. |
| title_fullStr | Safety profile of rivaroxaban in first-time users treated for venous thromboembolism in four European countries. |
| title_full_unstemmed | Safety profile of rivaroxaban in first-time users treated for venous thromboembolism in four European countries. |
| title_short | Safety profile of rivaroxaban in first-time users treated for venous thromboembolism in four European countries. |
| title_sort | safety profile of rivaroxaban in first time users treated for venous thromboembolism in four european countries |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0298596&type=printable |
| work_keys_str_mv | AT anaruigomez safetyprofileofrivaroxabaninfirsttimeuserstreatedforvenousthromboembolisminfoureuropeancountries AT taniaschink safetyprofileofrivaroxabaninfirsttimeuserstreatedforvenousthromboembolisminfoureuropeancountries AT annemarievoss safetyprofileofrivaroxabaninfirsttimeuserstreatedforvenousthromboembolisminfoureuropeancountries AT ronmcherings safetyprofileofrivaroxabaninfirsttimeuserstreatedforvenousthromboembolisminfoureuropeancountries AT elisabethsmits safetyprofileofrivaroxabaninfirsttimeuserstreatedforvenousthromboembolisminfoureuropeancountries AT karinswartpolinder safetyprofileofrivaroxabaninfirsttimeuserstreatedforvenousthromboembolisminfoureuropeancountries AT yaninabalabanova safetyprofileofrivaroxabaninfirsttimeuserstreatedforvenousthromboembolisminfoureuropeancountries AT gunnarbrobert safetyprofileofrivaroxabaninfirsttimeuserstreatedforvenousthromboembolisminfoureuropeancountries AT kilianasuzartwoischnik safetyprofileofrivaroxabaninfirsttimeuserstreatedforvenousthromboembolisminfoureuropeancountries AT luisalbertogarciarodriguez safetyprofileofrivaroxabaninfirsttimeuserstreatedforvenousthromboembolisminfoureuropeancountries |